Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. Newsome SD, Krzystanek E, Selmaj KW, Dufek M, et al. Neurology 2025;104:e213574.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Newsome SD, Krzystanek E, Selmaj KW, Dufek M, et al. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. Neurology 2025;104:e213574.
PMID: 40245351